Advancing EV Clinical Strategies: Overcoming Low Yields with Innovative Isolation Methods Introduction
Are you frustrated with low extracellular vesicle (EV) yields and inconsistent quality in your isolations? Conventional protocols often result in substantial EV loss, limiting their clinical application. In a innovative study published in Scientific Reports, ISEV 2025 presenter sara biagiotti introduce an innovative EV isolation and characterization method. Their approach significantly improves EV recovery while preserving essential bioactive markers, setting a new standard for clinical-grade EV preparations.
Read detailsRevolutionize Cancer Immunotherapy: How Shark-Derived Nanobodies Target CD22 to Solve Critical Therapeutic Challenges
Are you frustrated by the limitations of conventional antibody therapies for B-cell malignancies? CD22—a B-cell specific transmembrane glycoprotein that modulates B-cell receptor (BCR) signaling—is highly expressed on malignant B cells, making it a prime target for immunotherapy. Yet, traditional treatments often suffer from limited receptor engagement and poor tumor penetration. A recent study in Molecular Therapy Oncolytics demonstrates that shark-derived nanobodies may overcome these hurdles.
Read detailsThe Challenges of Overusing Alpacas in Nanobody Research
Alpacas have been a cornerstone of the nanobody industry, but are we overusing them? A recent Chinese report (source) reveals alarming insights into the repeated immunization and unclear histories of these animals. Here’s what’s reported:
Read detailsSearch Here
[searchandfilter id="20685"]